GPP

(.1)

Guideline to achieve
Mandatory GPP Regulation

.
.

: Good Pharmacy Practice (GPP)

..2556
..2510 (..1)
(..2)
(..3) (..4)
GPP

25 2557
8
(..1)
(GPP)
..2557
(..1)

GPP (Guideline to achieve mandatory GPP regulation)
(..1)

..2557

(..1)

..2557

1.
1.1

8


2

()

(Pharmacist-service area)
()
(Counseling area) (Pharmacistservice area)
(Pharmacist-service area) (Counseling area)
8 2

2
( 30 )

1.

2
( 30 )

1.

(Self-service area)

(Pharmacist-service area)
(Counseling area)

1.
1.2

()
(stock)
(Stock)

30 2 8

Chloramphenicol
( 2-8 )

stock ( 30 )
(Stock)

(Palette)

1.
1.3

(Counseling area) 2



(Counseling area)

(Counseling area)
(Pharmacist-service area) 2
(Counseling area)
(Pharmacist-service area)
1 (Counseling area)

1.
1.4

()
1.
1.5

/
2

10

1.
1.6

1.
1.7




30

-- ()
-- (Stock) ()
-- ( ) (

)
1

11

30
(Stock) 2 8
()

1.
1.8

(Daylight)

12

1.
1.9
1.9.1

1.9.2

(Pharmacistservice area)
()

-- (Gastro-intestinal system)
--
(Cardiovascular system)
-- (Respiratory system)
--
(Central nervous system)
-- (Infections)
-- (Endocrine system)
-- (Obstetrics,
Gynaecology)
--
(Urinary-tract disorders)
--
(Malignant disease and Immunosuppression)
-- (Vitamins and Minerals)
-- (Musculoskeletal and joint disease)
-- (Eye Ear Nose Oropharynx and Oral cavity preparations)
-- (Skin preparations)

13

--
--
--
--
--
--
--
--
--
-- /
-- //
--
-- /
--
--
--

(Look Alike Sound Alike Drugs (LASA Drug))

(Pharmacist-service area)

14

2.
2.1 1
(





)

(
) ( )
(
)

1 (

2 8 ) (
)

2 8

()

15

2.
2.2 2

(NSAIDs)

--
--
--
-- /
(//)
( ())

(Cross contamination)

16

2.
2.3 () 1

()

(Counseling area)


2.
2.4 1

2.
2.5 1

()

17

2.
2.6 1

1 200 .. (

4
)
() 150
30



-- ..2522 (
..2555)
-- ..2554 (

..2555)
-- ..2535 (
..2552)

150

18

3. ()
3.1

..2558
(CPE credit) 10
3.2

3.3

3
--
--
--

19

3. ()
3.4

20

3. ()
3.5

( )

3. ()
4.1

--
--
-- .
--
(GPP)

21

3. ()
4.2

30
2 8


(Stock)
1

30
(Stock) 2 8 (
)

22

3. ()
4.3

/
/
FEFO (First Expire First Out)
() ()

( 6 8 )
/


(Stock)



FEFO (First Expire First Out)

AAA
BBB
YYY
ZZZ

#1
#1
#2
#3

..2559 (2016)
.. .. .. .. .. .. .. .. .. .. .. ..
1
3
5 2
5
5
3
10

AAA #1 2559
1 2559 3 YYY
#2 2559 5 2559 5
(Stock Card)
(Stock)

23

(
#1)
AAA
BBB
CCC
DDD

.. / ()
2559
2560
2561
2562
..(1) ..(3)
..(5)
..(5) ..(2)
..(4)
..(5)

..(9)
..(10)
..(6)
..(5)

AAA 2559 1 2559
3 2560 5
( 6-8 )

.. 59

AAA

.. 59

ZZZ

.. 59

YYY

BBB 7 09 5 10
2 BBB 09 () 2559 5
10 () 2559 2 FEFO (First

24

Expire First Out)

( 6-8 )

6-8

.....

/ (Stock)
3. ()
4.4

25

3. ()
4.5

// //
/

-/
/

() (Lot.)
/
(/)

/
(Lot.)

4.6

()
5

( ..9)
( ..11)
( ..10)

( ..12)
( ..13) (
.)

26

1. ..9

/
3
( ..9)

4 2558

1 (Tramadol)
2
3
4

(Dextromethorphan)

(Corticosteroids)
(Sildenafil)
(Tadalafil)

(Vardenafil)

(Antihistamine)

1,000

2,000

1,000

1,000

.
(http://drug.fda.moph.go.th/)

27

2.

5 2558
..11

1. (Tramadol)

2. (Dextromethorphan)

3. (Antihistamine)
1. (Brompheniramine)
2. (Carbinoxamine)
3. (Chlorpheniramine)
4. (Cyproheptadine)
5. (Dexchlorpheniramine)

6. (Dimenhydrinate)

7. (Diphenhydramine)
8. (Doxylamine)
9. (Hydroxyzine)
10. (Promethazine)
11. (Triprolidine)

28

..11 ..9
..11 1 Lot. ( ..9) ..11
1 ..11 ..9
Lot

2 2558 Eifcof-G Lot.no. 1703340 50 (1 )

( ..9)
..11 1 Eifcof-G Lot.no. 1703340
Lot.

( 4 2558 )

29

1. (Tramadol)

2. (Dextromethorphan)

3. (Antihistamine)

-

- 20 //
- 17

-

- 3 (180 .)//
- 20 //

1. (Brompheniramine)
2. (Carbinoxamine)
3. (Chlorpheniramine)
4. (Cyproheptadine)

5. (Dexchlorpheniramine)

6. (Dimenhydrinate)
7. (Diphenhydramine)
8. (Doxylamine)
9. (Hydroxyzine)
10. (Promethazine)
11. (Triprolidine)

- 3 (180 .)//

3.
/
3 1
.10

30

(..10) (Zero order report)

..10 ..9
..10 1 Lot. ( ..9) ..10 1
..10 .. 9
Lot.

2 2558 Seretide Accuhaler Lot.no. 4ZP7166 3

Zuellig ..9
..10 1 Seretide Accuhaler
Lot.no. 4ZP7166 Lot.

31

4.
( .. 12)

()
(- ) (-
) /
..12

32

(..12)
..12 (Zero report)

5.

..13
. 4

33

3. ()
4.7

(Lot.)

() 2-8oC



(Chloramphenicol)
2-8


3. ()
5.1

34

60

( .1)

(
.1 3 )

3. ()
5.2

1.
2.
3. / /
4.
5.
6.
7. / /
8.

35

3. ()
5.3

5.3.1





5.3.2

()

1.
2.
3. ( )
4. /
5.
6. ()




..11

36

..2551

3. ()
5.4

(Side effect) ()
(Adverse
Drug Reaction)

/ / ()

37

3. ()
5.5

1.
2.
3.
consumer pack ( ())

4.

5.
6.

3. ()
5.6

(Sign and Symptoms)

--
--
-- (wheeze)
--
--
-- 3-4
-- (whooping cough)

38

--
--
--
--
--

--
--
--
--
--
--
--
--

--
--
--
--

--
--

--
--
-- //
--
--
-- ()

--
-- /
--
--
--

39

--
--
--
--
--
--


: * ( ..2554)

3. ()
5.7

40

3. ()
5.8

3. ()
5.9

/






3. ()
5.10

1.
2.
3.

41

4.
5. (
)
6. /
7.
8.
(.) (.)
2
(
) .xxxx/25xx

(, )
.xxxx/25xx

......../25.......
()

42

3. ()
5.11

4
1.
2.
3.
4.


3. ()
5.12

43

......................................................................

44

/ / Product Consultant (PC)

......................................................................

()

45

46

47

....................................... ...........

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

.
.
.
.
.
.
.
.
.
.
.
.
.
.

48

..

..

49

..

..

50

..